Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2021-08-02 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
2021年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2021 Half-Year Special Report on the Deposit and Actual Use of Raised Funds" by the company. It details the amount of funds raised through convertible bonds, the use and balance of these funds as of June 30, 2021, and compliance with regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The document includes detailed tables on fund usage, management, and storage, as well as auditor verification reports. It is a specialized report focused on the management and use of capital raised, not a full annual or interim financial report. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on fundraising and capital usage activities. The document length is about 4929 characters, which is sufficient to contain substantive content rather than just an announcement. Therefore, the appropriate classification is CAP with high confidence.
2021-08-02 Chinese
董事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 22nd meeting of the 4th Board of Directors of the company. It specifically mentions the approval of the 2021 half-year report and related reports, but does not contain the actual financial data or the report itself. Instead, it states that the full reports are published on an external website. The document is short (979 characters) and serves as a notice of the board meeting decisions and the approval of reports, not the reports themselves. Therefore, it fits the category of a Regulatory Filing (RNS) as it is an official announcement related to corporate governance and report approvals but does not contain the full report or detailed financial data.
2021-08-02 Chinese
2021年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "健帆生物科技集团股份有限公司 2021 年半年度报告全文," which translates to "Jafron Biomedical Co., Ltd. 2021 Semi-Annual Report Full Text." It contains detailed financial data, management discussion and analysis, company business overview, product descriptions, and other comprehensive information typical of a semi-annual or interim financial report. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. The presence of financial metrics, management analysis, and detailed operational data confirms it is a substantive financial report for a period shorter than a full fiscal year. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-02 Chinese
独立董事关于公司第四届董事会第二十二次会议相关事项的独立意见
Audit Report / Information Classification · 95% confidence The document is an independent director's opinion on matters related to the company's 2021 semi-annual report, including external guarantees, related party fund occupation, and a special report on the use of raised funds for the half-year period ending June 30, 2021. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and it is dated August 3, 2021. The content is a formal opinion letter by independent directors rather than the full semi-annual report itself. The document length is short (744 characters), and it does not contain actual financial statements or substantive financial data, but rather an independent opinion on specific report-related matters. Therefore, it is not the interim/quarterly report (IR) itself but an audit or independent opinion related to the report. This fits best under Audit Report / Information (AR). H1 2021
2021-08-02 Chinese
半年报披露提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (463 characters) indicating that the company's 2021 half-year report and summary have been approved and will be published on a regulatory website. It does not contain the actual half-year financial report or substantive financial data but rather informs investors about the upcoming publication of the report. According to the MENU VS MEAL RULE, this is a Report Publication Announcement (RPA) rather than the Interim/Quarterly Report (IR) itself.
2021-08-02 Chinese
2021年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2021年半年度报告摘要" which translates to "2021 Half-Year Report Summary." It contains detailed financial data for the half-year period, including revenue, net profit, cash flow, and other financial indicators. It also discusses business operations, production expansion, R&D investment, social responsibility, and governance. The presence of comprehensive financial statements and substantive financial data for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is about 9,798 characters, which is sufficient to be a full report rather than a mere announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-02 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.